{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-023995","form_type":"8-K","ticker":null,"cik":"0001923840","company_name":"Third Harmonic Bio, Inc.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.585450+00:00","generated_at":"2026-05-26T23:31:41.064148+00:00","sec_items":["2.02","2.05","7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Third Harmonic Bio cuts workforce by 50%, expects $2.3M restructuring costs; cash runway extended","bullets":["Reducing headcount by ~27 employees (50%) under restructuring plan; completion expected by Q2 2025.","Estimated severance and exit costs of $2.3M, recorded primarily in Q1-Q2 2025.","Preliminary, unaudited cash and equivalents of ~$285M as of Dec 31, 2024.","Projected cash balance of $262M-$267M as of June 30, 2025 after THB335 Phase 2 readiness and restructuring costs.","Company refocusing on THB335 Phase 2 readiness as strategic priority."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-023995","json":"https://secwatch.observer/filing/0001193125-25-023995.json","markdown":"https://secwatch.observer/filing/0001193125-25-023995.md","text":"https://secwatch.observer/filing/0001193125-25-023995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1923840/000119312525023995/0001193125-25-023995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1923840/000119312525023995/d867173d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:31:41.064148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd4853783de527096e3c9b366eb6f385ce7a2c14","claim":"Third Harmonic Bio, Inc. announced a restructuring with charges of approximately $2.3 million (approximately 27 employees, representing an approximate 50%).","evidence_excerpt":"On February 11, 2025, the Board of Directors of the Company approved, and management began implementing, a restructuring plan (the “ Restructuring Plan ”) to reduce operating costs and better align its workforce with the needs of its strategic research and development strategy. The implementation of the Restructuring Plan should be substantially complete by the end of the second quarter 2025. Under the Restructuring Plan, the Company is reducing its overall workforce by approximately 27 employees, representing an approximate 50%. Impacted employees are eligible to receive severance benefits. These severance benefits are contingent upon an impacted employee’s execution (and non-revocation) of a severance agreement, which includes a general release of claims against the Company. The Company expects that it will incur approximately $2.3 million of aggregate severance and exit costs in connection with the Restructuring Plan, which will be recorded primarily in the first and second quarters","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1923840/000119312525023995/0001193125-25-023995-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.3 million"},{"label":"Headcount","value":"approximately 27 employees, representing an approximate 50%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}